SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending following its earnings report, where an EPS beat and optimistic full-year guidance have ignited hopes for a short squeeze among bulls, who emphasize the stock's oversold status and diversified growth. However, bears point to a revenue miss and continued concerns over competition and regulatory headwinds, leading to a highly divided community discussion on the stock's valuation and future.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is trending after reporting a beat on its recent earnings, yet the market reaction has been mixed, leading to community discussions about its high valuation and recent price dip. Bulls remain confident, citing continued contract wins in unmanned systems and hypersonics amidst a strong defense sector backdrop.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond (now Beyond, Inc.) is trending as recent financial results revealed declining revenue and ongoing cash burn, fueling community concerns about its profitability and the leadership of Marcus Lemonis amid new ventures into tokenization and acquisitions.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is facing a substantial stock drop after Anthropic's Claude AI unveiled new COBOL modernization capabilities, leading to market concerns about its impact on a core legacy business. Yet, community discussion points to this as an overreaction, highlighting IBM's existing partnership with Anthropic and its own robust AI and quantum computing initiatives.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending sharply lower after its experimental obesity drug, CagriSema, demonstrated less weight loss compared to Eli Lilly's rival treatment in a head-to-head trial. While some in the community view this as an overreaction and a buying opportunity given Novo's established GLP-1 portfolio and oral pill advantage, others express concerns about the company's competitive edge and leadership in the evolving weight loss market.

Keysight Technologies, Inc. engages in the provision of electronic design and test solutions that are used in the design, development, manufacture, installation, deployment, validation, optimization, and secure operation of electronics systems to communications, networking, and electronics industries. It operates through the Communications Solutions Group (CSG) and Electronic Industrial Solutions Group (EISG) segments. The CSG segment serves customers spanning the global commercial communications and aerospace, defense, and government end markets. The EISG segment offers test and measurement solutions across electronic industrial end markets, focusing on applications in the automotive, and energy industry and measurement solutions for semiconductor design and manufacturing, consumer electronics, education, and general electronics manufacturing. The company was founded by William R. Hewlett and David Packard in 1937 and is headquartered in Santa Rosa, CA.

Keysight Technologies Inc

Keysight Technologies is trending after reporting robust earnings and an optimistic outlook, driven by strong performance in AI data centers, 5G/6G technologies, and aerospace/defense. The community is actively discussing the company's successful pivot towards software and strategic acquisitions, fueling bullish sentiment.

Super Group (SGHC) Ltd. is a global digital gaming company, which engages in the global online sports betting and gaming businesses, Betway, a premier online sports betting brand, and Spin, a multi-brand online casino offering. It operates through the following segments: Betway, Spin, and Other. The Betway segment focuses on the ingle brand online sportsbook and online casino focused business with a global footprint and strategic partnerships. The Spin segment relates to the multi-brand online casino focused business with established market leadership in high-growth markets. The company was founded in July 2020 and is headquartered in St. Peter Port, the United Kingdom.

Super Group (SGHC) Limited

Super Group (SGHC) is trending following robust earnings, raised 2025 guidance, and a strategic exit from the U.S. market, with the community enthusiastically discussing its enhanced profitability, international growth, and recent stablecoin launch as potential drivers for a short squeeze.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is trending amidst widespread market concern and aggressive short-selling, driven by fears that new AI models will disrupt traditional software business models. This has ignited a polarized debate, with many believing the sector faces obsolescence while others contend valuations are deeply oversold and expect AI to ultimately enhance, rather than replace, established software platforms.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending following encouraging Phase 1 data for its T-cell engagers (VIR-5818 and VIR-5500) in oncology, showcasing promising safety and efficacy that has generated significant investor excitement and analyst upgrades. The community is actively discussing the potential for further upside, anticipating more updates from its differentiated pipeline, including Hepatitis Delta therapies and upcoming ASCO GU presentations, despite ongoing debates around cash runway and potential dilution.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is trending following a report highlighting how advanced AI agents could disrupt traditional payment business models, potentially bypassing interchange fees. This has ignited a split in community sentiment, with some fearing a foundational shift in finance while others see an overreaction, pointing to Mastercard's own initiatives in AI-driven payments and the enduring value of trust in transactions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ELEV Equity Corporate Actions Alert # 2025 - 378 
Information Regarding the Tender Offer of Elevation Oncology, Inc. (ELEV)  
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-378 
The tender offer by Concentra Biosciences, LLC to acquire all of the outstanding common stock of Elevation Oncology, Inc. (ELEV) is scheduled to expire one minute after 11:59 p.m. ET, on July 22, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on July 23, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on July 22, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (July 23) and will be suspended July 24, 2025.  
 
Tender offer is $0.36 and one non-tradeable CVR for each share of ELEV held.

The tender offer by Concentra Biosciences, LLC to acquire all of the outstanding common stock of Elevation Oncology, Inc. (ELEV) is scheduled to expire one minute after 11:59 p.m. ET, on July 22, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on July 23, 2025.

Nasdaqtrader

Equity Corporate Actions Alert #2025 - 378 Information Regarding the Tender Offer of Elevation Oncology, Inc. (ELEV)

StockTwits Web

Elevation Oncology Inc

 Equity Corporate Actions Alert # 2025 - 378 
Information Regarding the Tender Offer of Elevation Oncology, Inc. (ELEV)  


 
The tender offer by Concentra Biosciences, LLC to acquire all of the outstanding common stock of Elevation Oncology, Inc. (ELEV) is scheduled to expire one minute after 11:59 p.m. ET, on July 22, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on July 23, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on July 22, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (July 23) and will be suspended July 24, 2025.  
 
Tender offer is $0.36 and one non-tradeable CVR for each share of ELEV held.

Lisata Therapeutics Inc

CorMedix Inc

Outlook Therapeutics Inc

KalVista Pharmaceuticals Inc

Citius Pharmaceuticals Inc

Genprex Inc

Tempest Therapeutics Inc

Citius Oncology Inc.

TwongStocks

StockTwits For Android 

Aware Inc.

Intel Corp

Babcock & Wilcox Enterprises Inc

Asia Pacific Wire & Cable

Valens Semiconductor Ltd

New Horizon Aircraft Ltd

André Pol

@Mrvandepol Contingent value right. 

Any cash over $26.4m that ELEV has will be distributed to CVR holders. Also if they sell EO-1022 within 1 year, then CVr holders will receive 80% of any net proceeds from that deal over the next 5 years.

All of this was explained in the PR for the merger agreement
https://www.prnewswire.com/news-releases/elevation-oncology-enters-into-agreement-to-be-acquired-by-concentra-biosciences-for-0-36-in-cash-per-share-plus-a-contingent-value-right-302475956.html

Bob marks

PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

Prnewswire

Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right

 Contingent value right. 

Any cash over $26.4m that ELEV has will be distributed to CVR holders. Also if they sell EO-1022 within 1 year, then CVr holders will receive 80% of any net proceeds from that deal over the next 5 years.

All of this was explained in the PR for the merger agreement


@TwongStocks @Mrvandepol seems risky unless you know the odds of EO-1022 amounting to anything meaningful.  Personally I&#39;m not an expert in cancer antibodies

 seems risky unless you know the odds of EO-1022 amounting to anything meaningful.  Personally I'm not an expert in cancer antibodies